A sarcoma diagnosis can leave you looking for both a clear treatment plan and a broader conversation about your health. This guide brings together soft tissue sarcoma information, published regional hyperthermia research, and questions to discuss with Dr. Walter Lemmo, ND, and your sarcoma team.
LEMMO Integrated Cancer Care welcomes enquiries from people in Vancouver, Burnaby and across Metro Vancouver. Our approach considers your diagnosis, current treatment, everyday wellbeing and personal priorities. If you are searching for alternative treatments for sarcoma, start by understanding which approaches have evidence, what that evidence actually measured, and how an additional therapy would fit your oncology plan.
The key points
- Sarcoma is a family of cancers. The exact subtype, location, grade and stage affect the treatment discussion.
- Soft tissue sarcomas need individual assessment. Findings from one subtype or stage cannot automatically be applied to another.
- Regional hyperthermia has randomized trial evidence in a defined setting. The principal study added it to chemotherapy and local treatment for localized, high-risk soft tissue sarcoma.
- That evidence does not establish a standalone alternative cure. The device, temperature monitoring, combined treatment and patient selection matter. Read the study details below.
What are sarcomas and soft tissue sarcomas?
Sarcomas arise in connective and supporting tissues. Soft tissue sarcomas can develop in tissues such as fat, muscle, fibrous tissue, blood vessels and tissue around nerves. They may occur in a limb, the trunk, or deeper inside the abdomen. Bone sarcomas are a separate group; this page focuses mainly on adult soft tissue sarcomas. [4]
The word “sarcoma” alone does not describe enough to choose treatment. Examples of soft tissue sarcoma diagnoses include liposarcoma, leiomyosarcoma, undifferentiated pleomorphic sarcoma, synovial sarcoma and angiosarcoma. These names describe different diseases rather than interchangeable labels. Gastrointestinal stromal tumours (GISTs) also require their own treatment discussion. [14]
For your appointment, write down the exact wording from the pathology report. If a report uses an unfamiliar term, ask your treating team to explain it before comparing your situation with something you have read online. A useful first question is: “Which details of my particular sarcoma are driving the recommendation?”
Diagnosis, grade and stage: getting the details right
Symptoms and assessment
A soft tissue sarcoma may first appear as a lump or swelling, sometimes without pain. Deeper tumours may cause symptoms related to their location or pressure on nearby structures. A new, persistent or enlarging lump deserves medical assessment; its appearance alone cannot confirm or exclude sarcoma. [5]
Imaging and biopsy
Diagnosis commonly involves imaging and a biopsy. MRI can help assess a lump in an arm or leg; CT may help evaluate the abdomen or chest. A pathologist examines the tissue sample to establish the diagnosis and provide information such as subtype and grade. Scans and laboratory testing may also help the team plan treatment. [6]
Ask whether the imaging and pathology have been reviewed by clinicians experienced in sarcoma, whether any additional tissue testing would change the plan, and who will coordinate those results. Bring the actual reports to a consultation, rather than relying only on a short description or a remembered stage number.
Grade is different from stage
Grade describes microscopic features associated with how the tumour may behave. Pathologists consider features such as how different the cells look, how actively they are dividing and areas of dead tumour tissue. Higher-grade soft tissue sarcomas generally have a greater tendency to grow and spread. [7]
Stage describes the extent of disease. The staging system depends in part on the anatomical site and may incorporate tumour size, grade and spread. Localized disease, a recurrence in the original area, and metastatic disease are different clinical situations. These distinctions also matter when comparing your diagnosis with a research population. [8]
How soft tissue sarcoma treatment is planned
Surgery is a central treatment for many localized soft tissue sarcomas. Radiation therapy may be used before or after an operation, while chemotherapy or other systemic treatment may be appropriate in selected situations. Treatment choices depend on factors including subtype, location, size, spread and overall health. A multidisciplinary sarcoma team can explain both the sequence of treatment and its purpose. [9]
Some decisions concern control of the tumour in its original location; others concern disease elsewhere in the body. Your team may also discuss targeted therapies or clinical trials when appropriate to the diagnosis. A treatment used for one subtype or stage may have little relevance to another. [10]
Ask for the plan in everyday language: Is the intention to remove the cancer, reduce the risk of it returning, control advanced disease, preserve function, relieve symptoms, or address several of these goals? Understanding the goal makes it easier to assess the value and burden of any additional intervention.
What is local or regional hyperthermia?
Hyperthermia uses controlled heating of tissue as part of cancer treatment. Local hyperthermia focuses on a smaller area; regional hyperthermia heats a larger region, such as part of a limb or the pelvis. “Loco-regional hyperthermia” is another term patients may encounter. Different techniques deliver heat in different ways. Clinical hyperthermia is usually studied in combination with treatments such as chemotherapy or radiation. [11]
The proposed role is to increase the effect of a partner treatment in the heated area. However, a biological explanation is only a starting point. To assess a clinical claim, look for outcomes in people with a comparable diagnosis, a clearly described treatment protocol and an appropriate comparison group.
The treatment method matters
Ask how the proposed heating system, quality assurance and temperature monitoring compare with the published protocol. Do not assume that heat applied at home, a sauna, or a wellness treatment is clinically equivalent.
Likewise, evidence for that regional protocol does not by itself demonstrate equivalent results for whole-body hyperthermia, modulated electro-hyperthermia, another local device, or a different combination of drugs. Ask a provider to identify exactly which research supports the method being proposed for you. The clinic’s loco-regional hyperthermia information offers a starting point for that conversation; the research below should not be read as confirmation that the clinic uses the trial protocol.
Published studies: hyperthermia and soft tissue sarcoma
The first two publications below describe the same EORTC 62961–ESHO 95 trial at different follow-up times. They should be considered together, rather than counted as two independent randomized trials. The third study examined a different combination involving radiotherapy.
Regional hyperthermia added to chemotherapy — Issels et al., 2010
Published in The Lancet Oncology. Researchers randomized 341 patients with localized, deep sarcomas ≥5 cm, grade 2 or 3, to etoposide/ifosfamide/doxorubicin chemotherapy with or without regional hyperthermia, alongside local treatment.
This endpoint measures time until local tumour progression, local recurrence or death. It is not a cure rate.
“regional hyperthermia increases the benefit of chemotherapy”
Issels and colleagues, 2010 · excerpt from the interpretation
How to interpret it: The benefit concerns the studied combination. Pain, pressure discomfort and burns occurred; severe leukopenia (low white blood cell counts) was more frequent with combined treatment.
Read the full published trial ↗Long-term outcomes — Issels et al., 2018
Published in JAMA Oncology. This analysis included 329 eligible patients with a median follow-up of 11.3 years. It examined longer-term outcomes after chemotherapy with or without regional hyperthermia.
The hazard ratio was 0.73 (95% confidence interval, 0.54–0.98). Deaths from sarcoma or its treatment were counted; deaths from other causes were censored. These figures should therefore not be described as all-cause overall survival.
“For patients who are candidates for neoadjuvant treatment, adding regional hyperthermia may be warranted.”
Issels and colleagues, 2018 · concluding statement
How to interpret it: Nearly all participants underwent surgery; about two-thirds received postoperative radiotherapy. Benefit was not established separately for every anatomical or histological subgroup. Individual outcomes and other heating protocols cannot be inferred.
Read the published follow-up ↗Hyperthermia with preoperative radiotherapy — Maguire et al., 2001
Published in the International Journal of Hyperthermia. This study enrolled 35 adults and investigated a thermal-dose measure during hyperthermia combined with radiotherapy before surgery.
Among 29 evaluable patients with heatable tumours, 15 had a pathological complete response (52%), below the study’s prespecified target. Treatment-related toxicity occurred in 10 of 30 patients with heatable tumours.
“no correlation of thermal dose with histologic response was observed”
Maguire and colleagues, 2001 · excerpt from the results
How to interpret it: A pathological response describes the tissue examined after treatment, not a guarantee of lasting cancer control. There was no randomized radiotherapy-only comparison, so this small study cannot isolate the contribution of hyperthermia or establish a survival benefit.
Read the published study abstract ↗Could this research apply to your sarcoma?
A positive trial is most useful when its participants and treatment resemble your situation. Before drawing a conclusion, work through these questions with your sarcoma specialist and any clinician offering an additional therapy:
- Diagnosis: Did the study include my exact subtype, or only a broader group?
- Extent of disease: Was the cancer localized, recurrent or metastatic? Does that match my scans?
- Partner treatment: Was heating combined with the same chemotherapy or radiotherapy I am receiving?
- Technique: What device, heating target, temperature monitoring and quality assurance were used?
- Outcome: Did the study measure tumour shrinkage, local control, survival, symptoms or quality of life?
- Practical fit: Would appointments interfere with surgery, systemic treatment, rehabilitation or time at home?
- Accountability: Who will monitor side effects, assess benefit and decide whether to continue?
Bring the actual study link to your appointment. Ask the clinician to explain which parts support the recommendation and which parts remain uncertain. A proposed treatment should have a defined purpose, a monitoring plan and an explanation of its costs and alternatives.
Hyperthermia risks and treatment coordination
Hyperthermia requires appropriate equipment and clinical expertise. Uneven heating can cause discomfort, pain, blisters or burns. Risks vary with the technique and the treatments given alongside it. A clinician should assess suitability and explain how temperatures and symptoms will be monitored. [11]
Before a consultation, prepare a list of current medicines, supplements, implanted devices, previous operations and radiation treatments, and any changes in sensation or skin condition near the proposed treatment area. Ask how those details affect assessment. Do not assume that a non-surgical treatment is risk-free or that a published benefit means it is appropriate in every situation.
Make sure you know whom to contact if a concern develops between sessions. Agree on how recommendations will be communicated to your oncology team and how the plan will be reconsidered if your cancer treatment or general health changes.
Integrative support and alternative treatments for sarcoma
People looking for alternative sarcoma treatments in Vancouver may want more time to ask questions, help with daily symptoms, or a careful assessment of therapies they have encountered online. An integrative consultation can organize those concerns around the cancer care you are already receiving.
Complementary therapies are used alongside conventional care; alternative therapies are used in its place. Evidence and safety vary, and natural health products can interact with cancer medicines. Review proposed supplements and therapies with your treatment team. The studies on this page do not establish a natural product, diet or hyperthermia alone as a substitute for sarcoma treatment. [12]
Function, comfort and recovery
Soft tissue sarcoma and its treatment can affect movement, daily activity, body image and emotional wellbeing. Rehabilitation and supportive care may address problems such as reduced range of motion, swelling or the effects of limb surgery. Your needs may change during treatment and recovery. [13]
For an appointment with Dr. Walter Lemmo, ND, identify the priorities you most want to discuss: appetite, sleep, fatigue, comfort, coping with uncertainty, or understanding a proposed therapy. Ask what benefit is realistic, what evidence supports it, whether it could interact with treatment and how improvement would be assessed. You can also read about our approach to integrative cancer care.
A sarcoma support consultation serving Vancouver and Burnaby
LEMMO Integrated Cancer Care is located at Suite 205, 3900 Hastings Street, Burnaby, BC V5C 6C1, serving people from Vancouver and the wider Metro Vancouver area. Dr. Walter Lemmo is a naturopathic doctor with a practice focused on integrative cancer care. An enquiry about sarcoma support is an opportunity to discuss your situation, the clinic’s approach and whether a consultation would be useful.
The clinic describes an initial consultation of approximately one hour. No referral is required to contact the clinic. Ask the team about in-person or virtual consultation availability, fees and the appropriate way to provide medical records. This is separate from any referral needed for specialist oncology services.
What to prepare
- Your pathology report, including the exact subtype and grade, plus relevant molecular test results.
- Recent scan reports and a short timeline of diagnosis, operations, radiation and drug treatments.
- A complete medication and supplement list, with names, amounts and frequency.
- Any current symptoms or functional difficulties, and the two or three concerns that matter most to you.
- Links to therapies or research you would like explained, including the studies below.
- The names of the clinicians coordinating your oncology care and any upcoming treatment dates.
Bring your questions. Start with your situation.
Contact our team to ask about sarcoma support with Dr. Lemmo and preparing for your first visit.
By appointment · Monday–Friday, 9:00 am–5:00 pm · New patient information · Location and directions
Frequently asked questions
Can hyperthermia cure soft tissue sarcoma by itself?
The studies summarized here do not establish that. Their findings concern combined treatment, including chemotherapy or radiotherapy and, where applicable, surgery. If a treatment is described as a cure, ask for evidence in patients with your specific diagnosis and stage. Return to the research summaries.
Does the research apply to metastatic sarcoma or bone sarcoma?
The main randomized trial concerned localized, high-risk soft tissue sarcoma. It cannot, on its own, establish benefit for metastatic sarcoma or primary bone sarcoma. Those situations need their own evidence review and specialist discussion. [1]
Is regional hyperthermia the same as whole-body hyperthermia?
No. The area heated, equipment and treatment protocols differ. A result from one approach should not be assumed to apply to another. Confirm the precise technique being discussed. [11]
Can I discuss alternative treatment ideas with Dr. Lemmo?
You can contact the clinic about an integrative consultation and bring specific questions or published papers. Be clear about your current oncology plan and the decision you are trying to make. A useful discussion identifies potential benefits, uncertainties, interactions and practical next steps.
Does the clinic provide the exact regional protocol used in the trial?
This page does not establish that. Ask the clinic to confirm the equipment, clinical protocol, monitoring and availability relevant to your case, and ask your sarcoma team how closely any proposed treatment matches the evidence.
Where is the clinic for patients travelling from Vancouver?
The clinic is on Hastings Street in Burnaby, serving Metro Vancouver. Check our location and directions and confirm your appointment before travelling. For people farther away, ask which consultation formats are available for your location.
Published studies and further reading
Follow the links to the original publications and patient resources. Publisher access may vary; PubMed provides publication details and abstracts where available.
- Issels RD et al. Regional hyperthermia plus chemotherapy: randomized trial. Lancet Oncol. 2010;11(6):561–570. DOI: 10.1016/S1470-2045(10)70071-1. Full study · PubMed.
- Issels RD et al. EORTC 62961–ESHO 95: long-term follow-up. JAMA Oncol. 2018;4(4):483–492. DOI: 10.1001/jamaoncol.2017.4996. Published follow-up.
- Maguire PD et al. Thermal dose and response: phase II thermoradiotherapy study. Int J Hyperthermia. 2001;17(4):283–290. DOI: 10.1080/02656730110039449. Published study abstract.
- Canadian Cancer Society. What is soft tissue sarcoma?
- Canadian Cancer Society. Signs and symptoms of soft tissue sarcoma.
- Canadian Cancer Society. Diagnosis of soft tissue sarcoma.
- Canadian Cancer Society. Grading soft tissue sarcoma.
- Canadian Cancer Society. Stages of soft tissue sarcoma.
- Canadian Cancer Society. Treatments for soft tissue sarcoma.
- National Cancer Institute. Soft Tissue Sarcoma Treatment (PDQ), patient version.
- National Cancer Institute. Hyperthermia to Treat Cancer.
- BC Cancer. Complementary and Alternative Therapies.
- Canadian Cancer Society. Supportive care for soft tissue sarcoma.
- Canadian Cancer Society. Types of soft tissue sarcoma.
Sources checked 13 September 2026. This guide provides general education, not an individual treatment recommendation. Decisions about sarcoma care should be made with your qualified healthcare team. About medical information on this website.